Reportable range of quantitative assays for SARS-CoV-2 antibodies determination. An overlooked issue?

In order to identify the quantization capability of two methods for SARS-CoV-2 IgG determination (Anti-SARS-CoV-2 QuantiVac ELISA IgG from Euroimmun and SARS-CoV-2 IgG anti-RBD from SNIBE), the linearity of the reportable range with respect to the calibration curve was evaluated. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Not applicable All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The data referred in the manuscript are available.